Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endothelial-specific molecule 1 (EDIL3)
- Target
- EDIL3
- Molecular classification
- Secreted extracellular matrix glycoprotein
01
Overview
Endothelial-specific molecule 1 (EDIL3), also known as Del-1, is a secreted extracellular matrix protein primarily expressed by endothelial tissues during embryonic vascular development. In adults, expression is generally low but can be re-induced under pathological conditions. EDIL3 promotes angiogenesis, endothelial cell survival, and modulates immune cell recruitment. It interacts with integrins via an RGD motif and influences LFA-1/ICAM-1 interaction. It is overexpressed in some tumors, potentially contributing to abnormal neovascularization and immune exclusion.
- Other names
- Del-1Developmental endothelial locus-1Integrin-binding DEL1
02
Mechanism of action
Modulation of angiogenesis, leukocyte adhesion, and endothelial cell survival
03
Biological functions
Angiogenesis promotionEndothelial survivalImmune modulationCell adhesionCell migration
04
Disease associations
CancerIschemic injury
05
Safety considerations
Potential for promoting tumor angiogenesisImmune exclusion from tumors
06
Biomarkers
Circulating EDIL3 levels as a correlate with VEGF concentrations
Beyond the preview
Go deeper on Endothelial-specific molecule 1 (EDIL3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endothelial-specific molecule 1 (EDIL3).